Le réseautage au pouvoir synergique – Together for Synergistic Results

Events

June Networking Event: Biomedical and Healthcare

19/06/2018 - 06:30 PM
Share :  

BioTech Annecto Montreal is pleased to announce a presentation given Luca Genovesi, PhD, Principal Scientist, at Biotrial entitled:   

 

Bioanalytical method validation in drug development: CRO perspective


Bioanalytical method validation employed for the quantitative determination of drugs and their metabolites concentration in biological fluids plays a significant role in the drug development and it’s strictly regulated by different agencies across the globe. This presentation provides a quick glance at the pathway that a new drug needs to follow to enter in to the market. Particular focus will be given to the quantitation of small molecules and biologics in different stage of drug development. Samples preparation and analytical techniques will be illustrated to understand the complex work that is behind a CRO business.

 

Luca is a Principal Scientist at Biotrial dedicated to LC-MS Large Molecule quantitation, within the Method Development Group. He obtained his PhD in Industrial Biotechnology at the University of Milano Bicocca (Milan, Italy) with a focus in mass spectrometry. Before joining Biotrial Pharma, Luca was Senior Scientist and Technical leader both in pharmaceutical industry as well as different CROs. Luca has more than ten years of experience in protein mass spectrometry. He is also content administrator for the CRO focus group within the American Association of Pharmaceutical Science.

 

Who is invited?

Professionals in the following industries: pharmaceuticals, CROs, biotechnology, and medical technology, Health care and biomedical research

People seeking opportunities to enlarge their professional network in life science industries.

 

When and Where?

6:30pm to 9pm on Tuesday June 19, 2018

 

Pub L’île Noire

1649 rue St-Denis

Montréal (Québec)

  

Cost: $15 (up to 48h before the event) / $20 regular price / FREE if you purchase a yearly membership

 

Please login to the site, using LinkedIn preferably, to be able to register for the event.

May Networking Event: Biomedical and Healthcare

29/05/2018 - 06:30 PM
Share :  

BioTech Annecto Montreal is pleased to announce a presentation given by 

Michael Kong, PhD, Director, Medical Science Liaison (speaking on behalf of Graham Wood, PhD, Chief R&D Officer) at Altasciences Clinical Research (Algorithme Pharma ), entitled:   

 

Clinical Pharmacology Studies with Cannabis or Specific Cannabinoids

 

Cannabis has been used for years as a medicinal product. However, only a few cannabis-based therapies have proceeded through regulatory approval as drugs or botanicals. With the huge interest in the ability of cannabis or products with specific cannabinoids to treat a wide range of therapeutic areas, there are now a number of sponsors looking at the drug or botanical approval pathway with Health Canada and the FDA. This presentation will review the regulatory pathways that can be used for cannabis-based therapies. We will also review the clinical pharmacology studies that will be required for approval, starting with first-in-human studies and including the later stage studies, such as human abuse potential or testing drug effects on driving performance.

 

Dr. Wood has a Ph.D. in Neurology and Neurosurgery from McGill University. He joined Altasciences Clinical Research as Executive Vice President, Phase I Clinical Development, in November 2015. Since 1999, his focus has been on clinical pharmacology, managing three new molecular entities from toxicology to Phase IIa and over twenty from first-in-human to Phase IIa. Dr. Wood has conducted over 400 clinical pharmacology studies with companies such as Phoenix International, MDS Pharma, Allied Research and Cetero. Dr. Wood’s roles have varied from Project Management, Business Development and Clinical Operations. More recently, he was CEO at Manna Research (a late phase clinical CRO) and Chief Science Officer at Akesis.

 

Who is invited?

Professionals in the following industries: pharmaceuticals, CROs, biotechnology, and medical technology, Health care and biomedical research

People seeking opportunities to enlarge their professional network in life science industries.

 

When and Where?

6:30pm to 9pm on Tuesday May 29, 2018

 

Pub L’île Noire

1649 rue St-Denis

Montréal (Québec)

H2X 3K4

 

Cost: $15 (up to 48h before the event) / $20 regular price / FREE if you purchase a yearly membership

 

April Open Networking Event

24/04/2018 - 06:30 PM
Share :  

BioTech Annecto Montreal has the pleasure of inviting you to our April open networking event. 


Why participate?

To meet up with old friends and to widen your professional network

To exchange about new updates and trends in Life Sciences industries in Montreal and worldwide. 

 

Who is invited?

Professionals in the following industries: pharmaceuticals, CROs, biotechnology, and medical technology, Health care and biomedical research

People seeking opportunities to enlarge their professional network in life science industries.

 

When and Where?

6:30pm to 9pm on Tuesday April 24, 2018

 

Hurley's Irish Pub

1225 rue Crescent

Montréal (Québec)

H3G 2B1

 

Fees?

Members - $0 with purchase of yearly membership. Yearly membership: Exclusively now is $65, at http://ow.ly/zU9f6

Non-members – Special: $15 (up to 48h before the event) / $20 at the door

March Networking Event: Biomedical and Healthcare

20/03/2018 - 06:30 PM
Share :  

BioTech Annecto Montreal is pleased to announce a presentation given by Damon Smith, PhD, CEO at Altus Formulation Inc entitled:   

 

Development of a New, Injectable COX-2 Analgesic to Reduce Opioid Use after Surgery

 

Postoperative pain affects over 80% of people undergoing surgery and is too frequently treated with prolonged doses of opioids. Such strategies can lead to dependence and addiction.

 

We are using SmartCelle nanotechnology to develop a new formulation of the highly insoluble COX-2 inhibitor celecoxib (Celebrex®). SmartCelle, by increasing the solubility of celecoxib many thousands of times allows, for the first time, intravenous administration of this non-opioid drug. Red blood cell binding by SmartCelle technology also appears to significantly increase celecoxib circulation time permitting >12hr activity from a single injection. Such approaches are expected to reduce significantly the need for opioid analgesics after surgery thereby greatly enhancing patient experience and reducing addiction potential.

 

Damon is a CEO and a founder member of the Altus team having worked for 10 years as Senior Vice President Research and Development at Labopharm Inc. Prior to joining Labopharm he spent time at Conjuchem, a Montreal start up, and prior to this was Executive Director of Development at Protherics, a UK based antibody development company listed on the London Stock Exchange. 

 

Who is invited?

Professionals in the following industries: pharmaceuticals, CROs, biotechnology, and medical technology, Health care and biomedical research

People seeking opportunities to enlarge their professional network in life science industries.

 

When and Where?

6:30pm to 9pm on Tuesday March 20, 2018

 

Siboire Brewpub

5101 St Laurent Blvd

Montreal, QC H2T 1R9

  

Cost: $15 (up to 48h before the event) / $20 regular price / FREE if you purchase a yearly membership

 

Please login to the site, using LinkedIn preferably, to be able to register for the event.

New Year celebration - Open Networking Event

16/01/2018 - 06:00 PM
Share :  

 

Seasons Greetings!

 

For our next event, the BioTech Annecto Montreal team has partnered with Montreal CRA School to welcome you to a networking event to kick off the New Year! This is the perfect opportunity to fulfil your new years resolution to network and meet new people working in the pharmaceutical, CRO and biotechnology sectors. Come and join us for drinks and delicious finger food in a warm and cozy setting.

 

LAST UPDATE!

BioTech Annecto Montreal is pleased to announce a presentation given by Kevin Chen, CEO and Co-founder at Hyasynth Bio, entitled  

 

Creating the Cannabinoid Industry

 

Cannabinoids, which are most commonly known as the active compounds of cannabis, are some of the most interesting compounds in science and society. However, there are still many hurdles in the production and sale of cannabinoid products that will have to be overcome for the Canadian market to reach it's 6 billion dollars of potential. Kevin will talk about the recent news in industry and how his company, Hyasynth, are changing everything.

 

Don’t forget to tell your friends and colleagues!

 

Date: Tuesday, January 16, 2018

 

Time: 6pm

 

Where: 405 Ogilvy Avenue, Atrium in suite #101

Montreal, QC H3N 1M3

 

Just behind the metro station Parc. Free parking available.

 

Fees: $40 (members) / $45 (non-members, 48h in advance), $50 at the door.

Yearly membership: Exclusively now is $65, at http://ow.ly/zU9f6

 

Please login to the site, using LinkedIn preferably, to register for the event.

123456789